BioSpace News Archive

Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, announced that Steven Engle has joined the company as its Chief Executive Officer.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Board of Directors (Board) has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.

Lexaria Bioscience Corp. is pleased to announce the awarding of a European and United Kingdom DehydraTECH license for medical cannabis applications from Lexaria Pharmaceutical Corp. to Valcon Medical A/S (“Valcon”).

Sonnet BioTherapeutics Holdings, Inc. today announced that the Company’s 2022 Annual Meeting of Stockholders, on June 2, 2022 at 9:00 a.m. Eastern Time, was convened and adjourned, without any business being conducted, due to lack of the required quorum.

The Lung Cancer Mutation Consortium announces the initiation of trial sites at USC Norris Cancer Center, University of California-Davis, University of Michigan, and University of Washington for its fourth study, LCMC4 Evaluation of Actionable Drivers in EaRly Stage Lung Cancer, examining targeted drugs given as single agents and combinations as neoadjuvant therapies matched to specific genetic mutations.

Watchmaker Genomics announced it had secured $40 million in an oversubscribed Series A, bringing total funding to date to $53.5 million.

REVIAN Inc., today announced promising results from a study using the REVIAN RED System to treat patients with Central Centrifugal Cicatricial Alopecia (CCCA) were presented at the Society for Investigative Dermatology Annual Meeting.

The global aneurysmal subarachnoid hemorrhage drugs market size was reached at $323.51 million in 2020, and is projected to surpass $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030.

According to QY Research Medical, the breast imaging technologies market size was valued at $3,737.83 million in 2020, and is projected to reach $8,133.80 million by 2030, growing at a CAGR of 8.1% from 2021 to 2030.

According to QY Research Medical, the contrast injector systems market size is expected to be worth around $1.5 billion by 2030, growing at a CAGR of 7.6% from 2021 to 2030.